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Abstract
Background: The impact of polymorphic cytochrome P450 CYP2D6 enzyme on oxycodone’s metabolism and clinical
efficacy is currently being discussed. However, there are only spare data from postoperative settings. The hypothesis of this
study is that genotype dependent CYP2D6 activity influences plasma concentrations of oxycodone and its metabolites and
impacts analgesic consumption.
Methods: Patients received oxycodone 0.05 mg/kg before emerging from anesthesia and patient-controlled analgesia
(PCA) for the subsequent 48 postoperative hours. Blood samples were drawn at 30, 90 and 180 minutes after the initial
oxycodone dose. Plasma concentrations of oxycodone and its metabolites oxymorphone, noroxycodone and
noroxymorphone were analyzed by liquid chromatography-mass spectrometry with electrospray ionization. CYP2D6
genotyping was performed and 121 patients were allocated to the following genotype groups: PM (poor metabolizer: no
functionally active CYP2D6 allele), HZ/IM (heterozygous subjects, intermediate metabolizers with decreased CYP2D6
activity), EM (extensive metabolizers, normal CYP2D6 activity) and UM (ultrarapid metabolizers, increased CYP2D6 activity).
Primary endpoint was the genotype dependent metabolite ratio of plasma concentrations oxymorphone/oxycodone.
Secondary endpoint was the genotype dependent analgesic consumption with calculation of equianalgesic doses
compared to the standard non-CYP dependent opioid piritramide.
Results: Metabolism differed between CYP2D6 genotypes. Mean (95%-CI) oxymophone/oxycodone ratios were 0.10 (0.02/
0.19), 0.13 (0.11/0.16), 0.18 (0.16/0.20) and 0.28 (0.07/0.49) in PM, HZ/IM, EM and UM, respectively (p = 0.005). Oxycodone
consumption up to the 12th hour was highest in PM (p= 0.005), resulting in lowest equianalgesic doses of piritramide versus
oxycodone for PM (1.6 (1.4/1.8); EM and UM 2.2 (2.1/2.3); p,0.001). Pain scores did not differ between genotypes.
Conclusions: In this postoperative setting, the number of functionally active CYP2D6 alleles had an impact on oxycodone
metabolism. The genotype also impacted analgesic consumption, thereby causing variation of equianalgesic doses
piritramide : oxycodone. Different analgesic needs by genotypes were met by PCA technology in this postoperative cohort.
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Introduction
While morphine represents the standard analgesic in a
postoperative setting, other opioids might be also suitable or even
advantageous. Oxycodone has been marketed since 1917 and has
found widespread use for the treatment of chronic pain,
specifically since a controlled-release formula is available. An
intravenous formula is now on the market or has been re-launched
in several countries. However, intravenous oxycodone is not a
standard opioid for postoperative pain management in most
countries, including Germany.
As polymorphic cytochrome P450 enzymes (CYP) are involved
in the metabolism, a pharmacogenetic impact on oxycodone’s
efficacy is discussed [1–3]. Formation of the active metabolite
oxymorphone depends on CYP2D6, whereas N-demethylation by
CYP3A via the major pathway produces noroxycodone, a
metabolite with weak antinociceptive properties. Both metabolites,
oxymorphone and noroxycodone, are further degraded to
noroxymorphone by CYP2D6 and CYP3A.
Previous experimental trials have demonstrated an impact of
CYP2D6 and CYP3A genotypes and enzyme activity on
oxycodone’s pharmacokinetics, pharmacodynamics and safety in
volunteers [2]. In contrast, there are sparse data from postoper-
ative settings and these have not confirmed genotype specific
oxycodone consumption and analgesic efficacy [1]. However,
surgeries resulted only in minor to medium pain intensities and no
difference in opioid consumption could be detected [1]. One
might speculate that the impact of genotypes on oxycodone
therapy is considerably more profound after major surgeries,
which necessitate higher postoperative opioid doses. Thus, possible
genotype associated differences in opioid needs may become
detectable.
The hypothesis of this study is that oxymorphone plasma
concentrations measured during the crucial early postoperative
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period after major surgeries vary according to CYP2D6 genotypes
with an impact on analgesic consumption. In order to translate
pharmacogenetic findings into clinical practice, CYP2D6 geno-
type dependent equianalgesic doses were calculated and compared
to piritramide, which is the standard opioid used in Germany. Its
metabolism is not dependent on CYP2D6 activity. Thus,
equianalgesic intravenous piritramide : oxycodone doses might
be helpful for clinicians as there is little experience with oxycodone
in a postoperative setting in many countries.
Methods
Patients
Approval for this prospective, observational association study
was obtained from the institutional review board of the Medical
Faculty of the University of Bonn. One-hundred-thirty-one
patients scheduled for elective major abdominal surgery or
thoracotomy gave written informed consent and were instructed
in the details of the study, the use of the patient-controlled
analgesia (PCA) device and the numeric rating scale for pain
intensities (NRS: 0 denotes no pain, 100 denotes worst pain
imaginable). Exclusion criteria were alcoholism, drug dependence,
use of CYP3A inducing or inhibiting substances, clinically relevant
compromised kidney or liver function, psychiatric diseases,
epilepsy, contraindication for the use of study medications, known
opioid intolerance, laparoscopic surgery, perioperative epidural
analgesia, serious perioperative complications and changes in
anesthetic procedure. Preexisting medication was documented and
discontinued only for the day of surgery with the exception of
drugs necessary for major co-morbidity, e.g. cardiac and
pulmonary diseases.
Clinical Study Protocol
General anesthesia was conducted according to a standardized
protocol [1,4]: propofol 2–3 mg/kg, fentanyl 0.15 mg and cis-
atracurium for induction and remifentanil, isoflurane and cis-
atracurium for maintenance of anesthesia. About 30 minutes
before termination of anesthesia oxycodone 0.05 mg/kg i.v.
(oxycodone hydrochloride: OxygesicH injekt, Mundipharma,
Germany) was given with a maximum intraoperative dose of
5 mg. Additionally, dipyrone 1 g i.v. or in case of contraindica-
tions to dipyrone acetaminophen 1 g i.v. was infused. Patients’
genotypes were unknown during the clinical part of the study.
Prophylactic antiemetic treatment before emergence of surgery
was performed in high risk patients for postoperative nausea and
vomiting (Apfel’s validated risk score $3, [5]) according to the
department’s protocol. After emergence from anesthesia, patients
were transferred to the postoperative anesthesia care unit (PACU).
The analgesic regimen in the PACU consisted of further doses of
oxycodone 1–2 mg if pain scores were.40 at rest. For subsequent
analgesic treatment on the general ward, patients could self-
administer intravenous bolus doses of 1 ml corresponding to
oxycodone 1 mg via a patient-controlled analgesia (PCA) device
(InjektomatH-CP PACOM, Fresenius AG, Bad Homburg, Ger-
many) with a lock-out time of eight minutes and no background
infusion. If pain management via oxycodone PCA had to be
terminated prematurely due to lacking efficacy or side effects, e.g.
emesis which could not be controlled by antiemetic medication,
the analgesic regimen could be changed to the standard treatment
piritramide. Dipyrone 5 g/day and in case of contraindications
acetaminophen 4 g/day was infused i.v. as basic non-opioid
analgesic regimen in all participants. This is according to the
hospital’s standard procedure and complies with the national
guidelines of a multimodal analgesic regimen [6].
During the 48-hour study period following initial opioid
administration, pain scores under rest and exercise/coughing
were recorded by the patients using the NRS. Nausea and
vomiting (absence or presence) were assessed regularly and treated
with antiemetics if needed. Observation time points were hourly
up to the eighth hour, at the twelfth hour, and then every six hours
up to the forty-eighth hour. Opioid consumption was documented,
and the analgesic consumption administered via the PCA device
was transferred to an electronic data base. As individual
experience and subjective estimation of pain and side effects
might differ considerably between investigators and patients, an
additional questionnaire was completed by the patients after
48 hours. The questions considered overall patient assessment of
pain management and whether the quantity of analgesics was
sufficient.
Genotyping
Blood samples were drawn at 30, 90 and 180 minutes after
opioid administration. After centrifugation, blood cells and plasma
were frozen separately at -80uC. All laboratory analyses were
performed after enrollment of the last patient, and the laboratory
staff were blinded to the patients’ data.
Genotyping for CYP2D6 *3, *4, *5, *6, *7, *8, *10, *41 and
gene duplication/multiduplication as well as for CYP3A5*3 (rs
776746, G6986A) was performed by PCR and real-time PCR as
described previously [4,7]. All alleles with no indicators for one of
the genetic variants investigated were categorized as ‘‘wild-type’’
(wt). For translation of the genotypes into a qualitative measure of
phenotype, CYP2D6 activity score of each subject was calculated
as the sum of the values assigned to each single allele [8]. Alleles
*3,*4,*5,*6,*7,*8 were assigned a value of 0, alleles *10,*41 a value
of 0.5, the wt allele a value of 1, and wtxN a value of 2 [8]. Four
CYP2D6 activity groups were compared: activity score 0
representing poor metabolizers (PM); activity score 0.5–1 repre-
senting heterozygous subjects carrying one non-functional allele or
a combination of a non-functional with an allele showing reduced
function (HZ/IM); activity score of 1.5–2 representing extensive
metabolizers or a combination of wild-type allele and reduced
function allele (EM); activity score 3 representing ultrarapid
metabolizers (UM) with a duplication/multiduplication of a
functional allele. Because some authors [2,9] also suggested a
contribution of CYP3A to plasma disposition of metabolites and
analgesic efficacy the CYP3A5*3 variant was investigated explor-
atively. Individuals were assigned to the group of low expressors
(CYP3A5*3/*3) or high expressors carrying at least one
CYP3A5*1 allele [10].
Plasma Concentrations of Oxycodone and Its Metabolites
Oxycodone, the metabolites oxymorphone, noroxycodone, and
noroxymorphone as well as the deuterated standards oxycodone-
d3, noroxycodone-d3, oxymorphone-d3 and hydromorphone-d3
were purchased from Cerilliant Corporation (Round Rock, TX,
USA). Methanol, water, formic acid (all of HPLC grade),
acetonitrile (hypergrade for LC/MS), borate buffer (pH 11), and
ammonium formiate were purchased from Merck (Darmstadt,
Germany); n-chlorbutane (for HPLC) was obtained from Sigma-
Aldrich (Steinheim, Germany).
HPLC mobile phase A consisted of water (HPLC grade) and
acetonitrile (90:10, v/v), mobile phase B consisted of water (HPLC
grade) and acetonitrile (10:90, v/v), both with 0.005 M ammoni-
um formiate and pH was adjusted to 3.5 by addition of formic
acid.
Quantification of oxycodone, oxymorphone, noroxycodone and
noroxymorphone was performed by a liquid chromatographic-
CYP2D6 Genotype and Oxycodone Metabolism
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mass spectrometric method with electrospray ionization in positive
mode. A previous procedure showed ion suppression effects for the
hydrophilic metabolites [11] and was modified: A mixture of
0.2 ml plasma, 20 ml methanolic internal standard solution (1 mg/
ml of oxycodone-d3, noroxycodone-d3, oxymorphone-d3 and
hydromorphone-d3) and 0.1 ml borate buffer were extracted with
1 ml n-chlorbutane. After centrifugation (40006g, 8 min), the
organic phase was transferred and evaporated to dryness under a
stream of nitrogen at 60uC. The residue was dissolved in 0.1 ml of
mobile phase B and a 10 ml-aliquot was used for chromatography.
LC-MS/MS system consisted of a Shimadzu LC 20 series
(Duisburg, Germany) high-performance liquid chromatography
system (binary pump, degasser, controller and autosampler)
coupled with an Applied Biosystems (Darmstadt, Germany) API
4000 QTrap triple quadrupole mass spectrometer. Chromato-
graphic separation was achieved on a Phenomenex (Aschaffen-
burg, Germany) Hydro RP column (150*2 mm; 4 mm) with a flow
of 0.5 ml/min and with following gradients: 0–15 min from 10%
to 100% mobile phase B, 15–20 min 100% mobile phase B, 20–
21 min from 100% to 10% mobile phase B, 21–25 min
equilibration with 10% mobile phase B. For mass spectrometric
detection in multiple ion monitoring mode (MRM), following
transitions from the molecular ions ([M+H+]+) were used:
oxycodone (316.1R298.0, 241.0), oxycodon-d3 (319.1R301.1,
244.1), oxymorphone (302.1R284.0, 227.2), oxymorphone-d3
(305.1R287.1, 230.1), noroxycodone (302.2R284.0, 187.0),
noroxycodone-d3 (305.1R287.0, 230.2), and noroxymorphone
(288.1R270.0, 213.0). For quantification, peak area ratios of the
analytes to the corresponding deuterated standards were calculat-
ed as a function of the concentration of the substances.
Noroxymorphone was quantified by referring its peak area to
the peak area of oxymorphon-d3 due to the lack of its deuterated
analogue. The limits of quantification were between 0.08 and
0.11 ng/ml. Precisions and matrix effects were checked according
to international guidelines and all criteria were fulfilled [12] The
data are summarized in Table 1.
Statistical Analysis
The primary study endpoint was the influence of CYP2D6
genotypes on metabolism and plasma concentrations of oxycodone
and its metabolites. As on demand administered drugs per se
require an alternative approach for analyses of drug and
metabolite concentrations due to varying amounts of oxycodone
being administered according to individual needs, mean metab-
olite ratios of oxymorphone/oxycodone plasma concentrations
were compared between genotype groups (ANOVA, consecutive
post hoc analysis using the Tukey-test). These ratios reflect the
CYP2D6 activity-related plasma concentrations of both ocyco-
done and oxymorphone at the time points for blood sampling [1].
From previous data it was conservatively assumed that in PM this
ratio was about one third of that in EM and UM with a standard
deviation being as high as the means of PM [1,13]. For CYP2D6
7–10% of Caucasian individuals are PM. A total minimum
number of at least 120 patients was calculated to provide sufficient
pharmacokinetic data for the PM group. The x2-goodness of fit
test was applied to all SNPs to ascertain whether they were in
Hardy-Weinberg equilibrium.
As a secondary endpoint, a comparison of genotype-dependent
cumulative analgesic consumption that measured titration doses in
the recovery room as well as delivered PCA bolus doses was
performed (repeated measures ANOVA). For analysis of equian-
algesic doses, a comparison to a cohort receiving the standard
treatment with piritramide, a synthetic opioid structurally related
to meperidine, was used. Depending on their body weight, patients
received piritramide 4–8 mg i.v. before the end of surgery. In the
PACU, further doses of piritramide 2–3 mg were titrated if pain
scores were .40 at rest. The setting used on the PCA device was
identical to the oxycodone group, however, the 1 ml bolus dose
consisted of piritramide 2 mg. This ratio was chosen due to a
lower relative analgesic potency of piritramide compared to
morphine [14,15].
Equianalgesic ratios piritramide : oxycodone were calculated
from piritramide doses versus oxycodone doses titrated in the
recovery room and from the delivered amount of the respective
opioid via PCA. For the opioid consumption via PCA the first
eight hours were represented in hourly intervals. Thereafter,
opioid consumption up to the 12th, 18th, 24th, 30th, 36th, 42nd and
48th hour (15 observation time points) was extracted from
electronic PCA protocols. Patients were allocated to genotype
dependent CYP2D6 activity groups with no (PM), one (HZ/IM)
or at least two active CYP2D6 alleles (EM+UM). Mean overall
equianalgesic ratios piritramide : oxycodone with standard
deviations (SD) and 95%-confidence intervals (95%-CI) were
calculated and compared by ANOVA followed by post-hoc
analysis.
For all analyses level of significance was defined as p,0.05 with
subsequent correction for multiple testing. Analyses were per-
formed by using the statistical software STATISTICA 10 (Stat
Soft, Inc. Tulsa, OK, USA).
Results
Demographic Data and Genotypes
In this trial, a total of 131 patients were enrolled. Complete data
for 121 patients on oxycodone could be analyzed (major urologic
surgery: 80 patients, major abdominal: 29, liver/pancreatic
surgery: 5, thoracotomy 4, major gynecological laparotomy: 3
patients). Ten patients had to be excluded due to violation of the
study protocol, need for prolonged postoperative mechanical
ventilation or surgical complications. Demographic and surgery-
related as well as frequency of genotype groups are displayed in
Table 2.
Table 1. Limits of detection (LOD; signal-to-noise ratio 3), limits of quantification (LOQ; three times the LOD), precision (at 100 ng/
mL), and matrix effects (comparison of analyte responses of post-extraction spiked samples to those of spiked samples).
LOD ng/ml LOQ ng/ml Precision % Matrix Effect %
Oxycodone 0.02 0.08 8.4 105.6
Oxymorphone 0.03 0.09 9.8 88.8
Noroxycodone 0.03 0.09 11.8 92.5
Noroxymorphone 0.04 0.11 14.9 78.8
doi:10.1371/journal.pone.0060239.t001
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CYP2D6 and CYP3A Genotypes
Of the participants enrolled, 104 were of German descent, the
remainder from other European countries (13), Arabia or Africa
(4). Genotyping was successful in all blood samples. The observed
CYP2D6 allele frequencies were 2.0% (95%-CI: 0.9/4.7) for *3,
17.4% (13.1/22.6) for *4, 2.9% (1.4/5.9) for *5, 0.6% (0.4/3.6) for
*6, 4.5% (2.6/7.9) for *10, 7.9% (5.1/11.9) for *41 and 2.1% (0.9/
4.7) for wtxN. The CYP2D6*7 allele was not detected. For
CYP3A5, the allele frequency of *3 was 94.1% (91.7/95.9). Allele
frequencies did not differ when considering subjects of European
descent only. There was no deviation of allele frequencies from
Hardy-Weinberg equilibrium (p-values .0.05) and results were in
agreement with data reported previously [16,17]. Considering
genotype dependent metabolic activity 6.6% and 4.1% of the
patients carried a CYP2D6 dependent activity score of 0 or 3
(Table 2). For CYP3A, 10.7% high expressors with at least one wt-
allele were detected (Table 2).
Genotype-Dependent Plasma Concentrations
Plasma concentrations of oxycodone and oxymorphone were
dependent on CYP2D6 activity groups. The resulting metabolite
ratio oxymorphone : oxycodone was lowest in PM and highest in
UM (p=0.001; Figure 1). The time course of plasma concentra-
tions showed lowest oxymorphone doses in PMs (comparison of
genotype groups by repeated measures ANOVA, p=0.004;
Figure 2). There was no difference in plasma concentrations for
noroxymorphone among CYP2D6 genotypes (concentrations at
30 minutes: PM 2.863.2, HZ/IM 2.261.7, EM 3.462.5, UM
2.962.5 ng/ml; p = 0.9). For CYP3A5*3/*3 carriers neither
plasma concentrations of oxycodone (p = 0.5), nor the concentra-
tions of noroxycodone (p = 0.4) or noroxymorphone (p = 0.8)
differed compared to those subjects carrying at least one wt-allele.
Analgesic Consumption and Efficacy
Sixty patients (PM: 3, HZ/IM: 24, EM: 32, UM: 1) needed an
additional oxycodone dose (3.364.3 mg) in the recovery room (no
difference between CYP2D6 genotypes). The cumulative oxyco-
done consumption up to the twelfth hour varied between the
CYP2D6 activity groups (Figure 3, repeated measures ANOVA,
p= 0.005; post-hoc analysis PM versus EM: p,0.001; PM versus
carriers of at leat one active allele: p = 0.002). For CYP3A activity
groups, no difference in analgesic consumption could be detected
(CYP3A high ecxpressors 20.769.6 mg oxycodone up to the
twelfth hour, CYP3A low expressors: 20.0610.5 mg). Pain scores
at rest and movement did not differ between CYP2D6 genoytpye
groups (Table 3) and none of the patients had to be switched to
analgesic rescue medication. The postoperative questionnaire
revealed a high-degree of patient satisfaction. Only two individuals
on oxycodone (PM:1, EM:1) judged pain management as
insufficient. Twelve patients (PM: 2, HZ/IM:4, EM:6, UM:0)
answered ‘‘no’’ to the question whether delivered opioid doses
were high enough.
For comparison of equianalgesic doses, an additional cohort of
125 patients on piritramide were analyzed. Demographic and
sugery-related data as well as genotypes and pain scores were
comparable to the oxycodone group (Tables 2–4). Equianalgesic
doses of piritramide versus oxycodone differed between CYP2D6
genotypes (Table 5). For the combined group of EM and UM this
ratio was higher compared to PM and HZ/IM (p,0.001).
Discussion
In patients receiving oxycodone for postoperative analgesia after
major surgery, the CYP2D6 genotype influenced the ratio of
plasma concentrations of oxymorphone/oxycodone as well as
analgesic consumption via PCA during the first 12 postoperative
hours. This confirms our hypothesis and demonstrates that
sufficiently high pain scores resulting in relevant analgesic needs
are necessary to detect genotype dependent differences.
Influences of CYP2D6 Genotypes on Plasma
Concentrations
The CYP2D6-dependent metabolite oxymorphone has a 40 to
45-fold higher m-opioid receptor binding affinity than oxycodone
[18–21] and has proved to be a more potent m-opioid receptor
agonist. However, its impact on analgesia is controversial since
formation of oxymorphone is not considered the major metabolic
pathway [18,22].
In a previous trial, plasma concentrations were measured
25 minutes after i.v. injection of oxycodone 5 mg (PM: 0.04 ng/
Table 2. Demographic and Perioperative Data.
PMa HZ/IMa EMa UMa
Number of patients (%) 8 (6.6) 38 (31.4) 70 (57.9) 5 (4.1)
Male/female 5/3 21/17 48/22 3/2
Age (years) 6369 58613 56615 50612
Body weight (kg) 82616 81633 86630 88620
Height (cm) 177610 165624 167632 17663
Duration of surgery (min) 192645 200682 203691 193673
ASA I/II/III/IVb 1/6/1/0 5/22/10/1 11/36/22/1 1/2/2/0
CYP3A5 *1/*1 or *1/*3
or *3/*3
0/0/8 0/4/34 0/9/62 0/0/5
Patients were clustered according to CYP2D6 genotypes. Measures represent
mean6SD or number (%) of patients.
a: PM= poor metabolizers, HZ/IM= heterozygous subjects or intermediate
metabolizers, EM= extensive metabolizers, UM= ultrarapid metabolizers.
b: ASA = American Society of Anesthesiologists physical status; I = healthy patient,
II =mild systemic disease, III = severe systemic disease, IV = severe systemic disease
that is a constant threat to life.
doi:10.1371/journal.pone.0060239.t002
Figure 1. Mean Ratio of Oxymorphone/Oxycodone Plasma
Concentrations depending on CYP2D6 Genotype Groups.
Boxes represent 1st and 3rd quartile; whiskers the 5th and 95th
percentiles. ANOVA p=0.001; Tukey-test: PM vs. UM: p = 0.009, HZ/IM
vs. UM: p = 0.005).
doi:10.1371/journal.pone.0060239.g001
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ml; EM: 0.12 ng/ml) [1]. Similar to the present findings
oxymorphone concentrations and the metabolite ratio oxymor-
phone : oxycodone varied depending on CYP2D6 genotypes, but
overall substance concentrations measured in plasma were lower
than in the present study, which might be due to different
laboratory techniques [1]. Furthermore, another panel of SNPs
was investigated resulting in a different classification of CYP2D6
activity status [1].
A decrease of oxymorphone concentrations and a shift to the N-
demethylation pathway was reported in subjects with blocked
CYP2D6 activity (by comedication with quinidine), which
resembles the PM status [23]. In 20 chronic-pain patients, co-
administration of paroxetine decreased plasma AUC of oxymor-
phone by 67% and increased AUC of noroxycodone by 100%, but
had no effect on oxycodone analgesia or the use of rescue
medication [22]. In contrast, the effect of paroxetine on plasma
concentrations of one single i.v. dose of oxycodone was negligible
in an experimental setting [3]. In these previous investigations,
either no genotyping was performed or no sufficient number of
subjects was enrolled to perform a genetic association study.
CYP3A Activity
The CYP3A4 pathway is described as quantitatively more
important [18] with the N-demethylated metabolite noroxycodone
showing poor antinociceptive effects [19,24,25]. CYP3A is the
most abundant CYP protein in the human liver, and the influence
of genetic variants on metabolism has been demonstrated in
immunosuppressive drugs with a narrow therapeutic index and
frequent side effects [26–28]. In contrast, data on other widely
used drugs metabolized by CYP3A are sparse. For healthy
volunteers, Samer and co-workers stated that oxycodone’s
pharmacokinetics is also modulated by CYP3A activity [29]. A
Figure 2. Plasma Concentrations of Oxymorphone. Oxymorphone concentrations were clustered to CYP2D6 genotype activity groups PM, HZ/
IM, EM and UM. Measures represent means with -SD. Comparison of genotype groups by repeated measures ANOVA, p = 0.004.
doi:10.1371/journal.pone.0060239.g002
Figure 3. Cumulative Oxycodone Consumption. Patients were allocated to CYP2D6 genotype groups. Data are presented as mean with -SD.
Repeated measures ANOVA, p= 0.005 for consumption up to the 12th hour. Thereafter, there was no significant difference after correction for
multiple testing.
doi:10.1371/journal.pone.0060239.g003
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higher noroxycodone/oxycodone ratio and a higher daily
oxycodone escalation rate was described in cancer patients
carrying the CYP3A5*3/*3 genotype [9], however, an association
of plasma concentrations and analgesic consumption to CYP3A5
genotype could not be confirmed in the present trial. It is well
described that comedication with voriconazole, itraconazole,
telithromycin, rifampin or ketoconazol produces considerable
changes in oxycodone’s pharmacokinetic [2,3,29–33] and even
foods like grapefruit juice can inhibit CYP3A activity with
respective interactions [34]. Several authors have pointed out that
dose adjustment of oxycodone might be necessary, when used
concomitantly with CYP inducers or inhibitors to either maintain
adequate analgesia or prevent overdosing [31,32]. However, data
from large-scale clinical studies are lacking thus far.
Genotype and Opioid Consumption
The central nervous system effects of oxycodone were described
as governed by the parent drug, with a negligible contribution
from its oxidative and reductive metabolites [18,22]. This
hypothesis was mainly based on the low contribution of CYP2D6
to the overall metabolism of this opioid [18,22], however, this
hypothesis was not confirmed in all human trials. Specifically in
some volunteer studies, oxymorphone did play a role for analgesic
efficacy in parallel to the clear-cut pharmacokinetic effects
described in nearly all publications in which this issue has been
addressed [1,13,29].
In experimental pain models enrolling a limited number of
volunteers, oxycodone analgesia was reduced in PM compared to
EM, whereas increased pharmacodynamic effects were described
in two UM [13,29]. Some case reports [35–38] as well as the
present results are in line with these findings. In contrast, no
Table 3. Pain Scores at Rest and Coughing/Movement.
Oxycodone Piritramide
PMa HZ/IMa EMa UMa
On arrival at the PACUb 40 (30/50) 43 (30/51) 30 (15/45) 27 (20/62) 40 (30/50)
2 hrs at rest 40 (30/40) 40 (30/45) 30 (20/40) 27 (20/37) 36 (30/44)
2 hrs at coughing 65 (60/70) 60 (50/70) 57 (50/70) 70 (50/80) 60 (50/70)
6 hrs at rest 27.5 (20/39) 30 (22/38) 26.6 (20/35) 25 (27/30) 30 (20/37)
6 hrs at coughing 55 (50/60) 57.5 (50/70) 50 (41/60) 70 (60/70) 50 (40/60)
12 hrs at rest 24 (16/30) 30 (20/33) 25 (15/30) 30 (30/30) 20 (11/30)
12 hrs at coughing 50 (48/60) 52.5 (50/60) 50 (40/60) 60 (60/70) 40 (39/50)
Patients treated with oxycodone were clustered according to CYP2D6 genotype groups. Additionally, the results of the piritramide groups are displayed. Pain scores are
presented as medians (1st/3rd quartile).
a: PM= poor metabolizers, HZ/IM= heterozygous subjects or intermediate metabolizers, EM= extensive metabolizers, UM= ultrarapid metabolizers.
b: PACU=post anesthesia care unit.
doi:10.1371/journal.pone.0060239.t003
Table 4. Demographic and Perioperative Data of 125 Patients receiving Piritramide.
Piritramide
Male/Female 69/56
Age (years) 56615
Body weight (kg) 79620
Height (cm) 170617
Duration of surgery (min) 210678
ASA I/II/III/IVa (no. patients) 18/71/33/3
Kind of surgery (no. patients)
Urologic (nephrectomy/enucleation of kidney tumor, prostatectomy) 81
Major abdominal (bowel resection) 32
Liver/pancreatic surgery 4
Thoracotomy (lung resection, thymectomy) 6
Major gynecological laparotomy 2
CYP2D6 genotype group: PM/HZ/IM/EM/UMb 13/39/69/4
CYP3A5 *1/*1 or *1/*3 or *3/*3 3/10/112
Data represent number of patients and means6SD.
a: ASA: American Society of Anesthesiologists physical status; I = healthy patient, II =mild systemic disease, III = severe systemic disease, IV = severe systemic disease that is
a constant threat to life.
b: PM= poor metabolizers, HZ/IM = heterozygous subjects or intermediate metabolizers, EM= extensive metabolizers, UM= ultrarapid metabolizers.
doi:10.1371/journal.pone.0060239.t004
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genotype dependent difference in analgesic consumption was
detected in a previous PCA study [1], but, no differentiation of
UM and HZ/IM was performed, surgical procedures were less
invasive and the 24 h oxycodone consumption was considerably
lower with about 40% of the patients not using the PCA device at
all [1]. The overall low analgesic needs might have masked
possible differences between genotypes. Stubhaug and co-workers
stated that a sufficiently strong base-line pain is necessary to
discriminate between drugs [39] or as in this case between
different genotypes. As hypothesized in the present trial, enrolling
patients undergoing major surgery PM needed more oxycodone.
A substantial change in the analgesic regimen for postoperative
PCA seems not to be necessary as PM could compensate higher
analgesic needs by demanding additional PCA bolus doses and
titrating themselves to comfortable low pain intensities. This is also
reflected by comparable pain scores in the different CYP2D6
activity groups.
The definition of equianalgesic doses of oxycodone to morphine
has been described as difficult due to pharmacokinetic differences
of the drugs [40]. For morphine:oxycodone a ratio of about 1.5
has been suggested [41–43]. In a further trial reporting a ratio of
1.0 in patients undergoing non-abdominal surgeries, high PCA
bolus doses (oxymorphone 30 mg/kg) might have contributed to
an increased overall opioid consumption [44]. Thus, possible
differences in opioid potency may have been concealed.
Equianalgesic doses of piritramide:oxycodone have not been
reported up to now. They are useful for clinicians in the case of
opioid switching. Piritramide is the preferred opioid in a
postoperative setting in several European countries due to rapid
onset, absence of active metabolites, and unproblematic use, also
in the case of impaired renal function [14,15]. Due to higher
oxycodone consumption in PM, the present trial revealed a
respective change in equianalgesic dose ratios piritramide:oxyco-
done compared to subjects carrying at least two wild-type alleles.
There are some limitations in the current study. First, the
overall number of patients included in this trial is limited.
Nevertheless, the results show a significant association between
CYP2D6 genotypes and oxycodone metabolism and consumption
at a statistical power of 80%. Second, for analysis of equianalgesic
doses piritramide:oxycodone a double-blinded study design might
have been suitable as well. However, as the patients’ genotypes
were unknown during the clinical part of the trial and the drugs
were administered via PCA by the patients themselves, the
influence of physicians and nurses on analgesic consumption
should be negligible. For more detailed evaluation of genotype-
associated oxycodone effects and side effects a larger patient
cohort needs to be investigated in a future trial. Additionally, the
influence of concomitant medication interfering with CYP activity
has to be addressed in a postoperative setting.
Conclusions
In this patient cohort recovering from major surgery and
requiring clinically relevant opioid doses, a CYP2D6 genotype-
dependent effect on plasma concentrations of oxycodone and
oxymorphone was detected. The higher oxycodone consumption
in PM resulted in genotype specific equianalgesic doses of
piritramide:oxycodone. PCA technology overcomes differences
in doses needed by various genotype groups, so that the PM also
experienced sufficient pain relief from oxycodone in this postop-
erative setting.
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